journal club presentation

Created using ChatSlide

This research, published in the "Current Medical Research and Opinion," explores the effectiveness of therapies for generalized myasthenia gravis (gMG), specifically Ravulizumab and Efgartigimod. Utilizing phase 3 trials, the study compares symptom control through MG-ADL, QMG, and MG-QOL15r measures, using R software for analysis. Findings indicate Ravulizumab offers consistent symptom stability over time, while Efgartigimod shows symptom fluctuation, necessitating treatment adjustments....